JP2017515508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515508A5 JP2017515508A5 JP2017512646A JP2017512646A JP2017515508A5 JP 2017515508 A5 JP2017515508 A5 JP 2017515508A5 JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017512646 A JP2017512646 A JP 2017512646A JP 2017515508 A5 JP2017515508 A5 JP 2017515508A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- hbv
- antigen
- subject
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700721 Hepatitis B virus Species 0.000 claims description 57
- 239000000427 antigen Substances 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 28
- 208000002672 hepatitis B Diseases 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 18
- 101710132601 Capsid protein Proteins 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 108700025184 hepatitis B virus X Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 241000710961 Semliki Forest virus Species 0.000 claims description 10
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 10
- 241000710929 Alphavirus Species 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 108091006027 G proteins Proteins 0.000 claims description 4
- 102000030782 GTP binding Human genes 0.000 claims description 4
- 108091000058 GTP-Binding Proteins 0.000 claims description 4
- 101710172711 Structural protein Proteins 0.000 claims description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 2
- 230000003044 adaptive effect Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 229940021993 prophylactic vaccine Drugs 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000013603 viral vector Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 15
- 241000700605 Viruses Species 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994166P | 2014-05-16 | 2014-05-16 | |
| US61/994,166 | 2014-05-16 | ||
| PCT/US2015/030100 WO2015175380A1 (en) | 2014-05-16 | 2015-05-11 | VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515508A JP2017515508A (ja) | 2017-06-15 |
| JP2017515508A5 true JP2017515508A5 (cg-RX-API-DMAC7.html) | 2018-06-21 |
Family
ID=54480490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512646A Pending JP2017515508A (ja) | 2014-05-16 | 2015-05-11 | 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9987353B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3143144A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017515508A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106459998A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015259470A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016026721A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2948181A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015175380A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002508A1 (en) * | 2016-01-12 | 2017-07-20 | Ulrike Protzer | Means and methods for treating hbv |
| EP3276006A1 (en) * | 2016-07-27 | 2018-01-31 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
| WO2018126042A1 (en) * | 2016-12-29 | 2018-07-05 | Virongy L.L.C. | Retro- and lenti-hbv hybrid vectors and constructs |
| CN108949790A (zh) * | 2017-10-27 | 2018-12-07 | 电子科技大学 | 一种基于基因工程烟草的1,2,3-三氯丙烷生物降解方法 |
| JP2021522864A (ja) * | 2018-05-10 | 2021-09-02 | クリアビー セラピューティクス リミテッド | Ｂ型肝炎感染症を処置するための方法および組成物 |
| US20210355168A1 (en) * | 2018-10-05 | 2021-11-18 | Rnagene Inc. | Chimeric antigen with enhanced multi-immune function through specific binding to target cell, and use thereof |
| MX2022003658A (es) | 2019-09-30 | 2022-04-25 | Gilead Sciences Inc | Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb. |
| EP4087858A1 (en) | 2020-01-10 | 2022-11-16 | Carogen Corporation | Compositions and methods of use of oncolytic virus like vesicles |
| CN113138276B (zh) * | 2020-01-19 | 2022-09-16 | 厦门万泰凯瑞生物技术有限公司 | 用于检测HBcAg的方法及抗体 |
| CN113234692B (zh) * | 2021-05-11 | 2022-02-22 | 华中农业大学 | 一种包含狂犬病毒糖蛋白的感染性克隆及应用 |
| CN113736750B (zh) * | 2021-09-22 | 2023-03-31 | 中牧实业股份有限公司 | 一株盖他病毒毒株及其应用 |
| WO2023133509A2 (en) * | 2022-01-08 | 2023-07-13 | Carogen Corporation | Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection |
| CN119110727A (zh) * | 2022-02-22 | 2024-12-10 | 卡罗根公司 | 用于感染性疾病和癌症免疫疗法应用的多功能病毒样囊泡(vlv)平台 |
| CN115747174A (zh) * | 2022-09-15 | 2023-03-07 | 武汉大学 | 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用 |
| KR20250103763A (ko) * | 2022-11-07 | 2025-07-07 | 시아먼 유니버시티 | 융합 단백질 및 이를 포함하는 입자형 항원 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030099932A1 (en) | 1998-05-12 | 2003-05-29 | Lorens James B. | Retroviral vectors with separation sequences |
| ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
| JP2009511636A (ja) * | 2005-10-18 | 2009-03-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | アルファウイルスレプリコン粒子による粘膜免疫および全身免疫 |
| US20100322965A1 (en) * | 2008-01-11 | 2010-12-23 | Rose John K | Viral vaccine vectors |
| AU2015259472A1 (en) * | 2014-05-16 | 2016-11-10 | Yale University | Evolution of high-titer virus-like vesicles for vaccine applications |
-
2015
- 2015-05-11 AU AU2015259470A patent/AU2015259470A1/en not_active Abandoned
- 2015-05-11 CA CA2948181A patent/CA2948181A1/en not_active Abandoned
- 2015-05-11 BR BR112016026721A patent/BR112016026721A2/pt not_active IP Right Cessation
- 2015-05-11 EP EP15793197.3A patent/EP3143144A4/en not_active Withdrawn
- 2015-05-11 CN CN201580025501.8A patent/CN106459998A/zh active Pending
- 2015-05-11 JP JP2017512646A patent/JP2017515508A/ja active Pending
- 2015-05-11 WO PCT/US2015/030100 patent/WO2015175380A1/en not_active Ceased
- 2015-05-11 US US15/305,180 patent/US9987353B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515508A5 (cg-RX-API-DMAC7.html) | ||
| US9987353B2 (en) | Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection | |
| JP2019526580A5 (cg-RX-API-DMAC7.html) | ||
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Zhang et al. | Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71 | |
| Wang et al. | Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice | |
| JP6259831B2 (ja) | Ｃ型肝炎ウイルスに対するキメラワクチン抗原 | |
| US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
| CN103757032B (zh) | 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法 | |
| Davis | DNA-based immunization against hepatitis B: experience with animal models | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| WO2005056051A2 (en) | Hepatitis b vaccines and compositions | |
| Zhou et al. | Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine | |
| JP2025504364A (ja) | 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン | |
| US20100322965A1 (en) | Viral vaccine vectors | |
| Edwards et al. | Developing mucosal vaccines for SARS-cov-2: What will it take? | |
| pertussis Novavax et al. | Covid-19 Vaccines: Several technologies at work | |
| De Ganzó et al. | Virus-Like Particles: Applications in Reverse Vaccinology | |
| RU2353651C2 (ru) | Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с | |
| HILLEMAN | Merck Institute for Therapeutic Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486, USA | |
| JP2008508890A6 (ja) | 組換え生鶏痘ウィルスベクター及びｃ型肝炎ウィルスに対する薬剤組成物中でのそれらの使用 | |
| Camus | Development and characterization of Lassa virus vaccines and mouse model |